Supplementary Figure 12 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors

Kyle Brandon Williams; Alex T. Larsson; Bryant J. Keller; Katherine E. Chaney; Rory L. Williams; Minu M. Bhunia; Garrett M. Draper; Tyler A. Jubenville; Wendy A. Hudson; Gunda I. Georg; Christopher L. Moertel; Nancy Ratner; David A. Largaespada

doi:10.1158/1535-7163.31248677

Supplementary Figure 12 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors

2026 Open access

Read full text

Authors: Kyle Brandon Williams, Alex T. Larsson, Bryant J. Keller, Katherine E. Chaney, Rory L. Williams, Minu M. Bhunia, Garrett M. Draper, Tyler A. Jubenville, Wendy A. Hudson, Gunda I. Georg, Christopher L. Moertel, Nancy Ratner

+1 more

David A. Largaespada

DOI: 10.1158/1535-7163.31248677

Cited by: 0

Abstract

Supplementary Figure 12 shows Kaplan Meier survival analysis and tumor volume measurements of a PDX treated with selumetinib, rigosertib, and the combination.

Fields of Study & Subjects

Neurofibromatosis and Schwannoma Cases Melanoma and MAPK Pathways Protein Tyrosine Phosphatases

Publication details

Publication date: 4 February 2026